Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Investigational therapies for hypercholesterolemia.

Expert opinion on investigational drugs·2017

Same author

Obesity diabetes and the role of bile acids in metabolism.

Journal of translational internal medicine·2017

Same author

Dyslipidaemia of diabetes and the intestine.

World journal of diabetes·2015

Same author

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

World journal of diabetes·2014

Same author

Investigational therapies for the treatment of atherosclerosis.

Expert opinion on investigational drugs·2014

Same author

The chylomicron: relationship to atherosclerosis.

International journal of vascular medicine·2011

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe - new anti-atherogenic properties?

Gerald H Tomkin¹

¹Diabetes Institute of Ireland, Beacon Clinic, Dublin, Ireland. gerald.tomkin@tcd.ie

British Journal of Pharmacology

|September 16, 2009

Summary

Ezetimibe and simvastatin benefit atheromatous plaques by improving monocyte/macrophage function and reducing nuclear factor-kappaB activity, independent of cholesterol absorption.

Area of Science:

Pharmacology
Cardiovascular Research
Atherosclerosis

Background:

Ezetimibe inhibits cholesterol absorption by targeting Niemann Pick C1-like1.
Ezetimibe may influence lipid accumulation in atheromatous plaques via monocyte lipid raft function, beyond cholesterol absorption.
Atherosclerosis involves complex inflammatory processes in plaque development.

Discussion:

Gómez-Garre et al. investigated the effects of ezetimibe and simvastatin on atheromatous plaques in a rabbit model.
Both ezetimibe and simvastatin demonstrated beneficial effects on plaque characteristics.
These effects may be mediated by modulation of monocyte/macrophage function and inhibition of nuclear factor-kappaB (NF-κB) activity.

Key Insights:

Ezetimibe and simvastatin impact atheromatous plaque progression through mechanisms beyond cholesterol reduction.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Modulation of immune cell function (monocytes/macrophages) plays a crucial role in plaque stabilization.

Inhibition of NF-κB signaling is a potential therapeutic target in atherosclerosis.

Outlook:

Further research is needed to determine if these findings in a rabbit model translate to human atherosclerosis.
Investigating the combined effects of ezetimibe and simvastatin on inflammatory pathways in human subjects is warranted.
Exploring novel therapeutic strategies targeting monocyte/macrophage function and NF-κB in cardiovascular disease is promising.